Individual investors among CStone Pharmaceuticals' (HKG:2616) largest shareholders, saw gain in holdings value after stock jumped 19% last week

Key Insights

• The considerable ownership by individual investors in CStone Pharmaceuticals indicates that they collectively have a greater say in management and business strategy
• The top 10 shareholders own 47% of the company
• Recent purchases by insiders

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Every investor in CStone Pharmaceuticals (HKG:2616) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are individual investors with 53% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

As a result, individual investors collectively scored the highest last week as the company hit HK$6.3b market cap following a 19% gain in the stock.

In the chart below, we zoom in on the different ownership groups of CStone Pharmaceuticals.

View our latest analysis for CStone Pharmaceuticals

What Does The Institutional Ownership Tell Us About CStone Pharmaceuticals?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that CStone Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see CStone Pharmaceuticals' historic earnings and revenue below, but keep in mind there's always more to the story.

CStone Pharmaceuticals is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is 6 Dimensions Capital Limited with 22% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 8.8% and 8.5%, of the shares outstanding, respectively. Furthermore, CEO Jianxin Yang is the owner of 1.3% of the company's shares.

A deeper look at our ownership data shows that the top 10 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of CStone Pharmaceuticals

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own some shares in CStone Pharmaceuticals. As individuals, the insiders collectively own HK$100m worth of the HK$6.3b company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

General Public Ownership

The general public, who are usually individual investors, hold a substantial 53% stake in CStone Pharmaceuticals, suggesting it is a fairly popular stock. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

Private Equity Ownership

With a stake of 30%, private equity firms could influence the CStone Pharmaceuticals board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Public Company Ownership

It appears to us that public companies own 8.5% of CStone Pharmaceuticals. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand CStone Pharmaceuticals better, we need to consider many other factors. For instance, we've identified 1 warning sign for CStone Pharmaceuticals that you should be aware of.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.